Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

75 76 Next >

What's Going On With Silence Therapeutics Stock Today? ↗

March 13, 2024

Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of...

Via Benzinga

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

March 13, 2024

From AstraZeneca

Via Business Wire

Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗

March 11, 2024

Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets.

Via Benzinga

Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates ↗

March 09, 2024

This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...

Via Talk Markets

Check Out What Whales Are Doing With AZN ↗

February 16, 2024

Via Benzinga

Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 ↗

March 07, 2024

Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...

Via Benzinga

Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic ↗

March 05, 2024

As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.

Via Benzinga

Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗

March 02, 2024

Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...

Via Talk Markets

Got $200? 2 Dividend Stocks to Buy and Hold Forever ↗

March 01, 2024

Trust these two real estate stocks to be attractively priced and proven performers.

Via The Motley Fool

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years ↗

March 01, 2024

It will take a lot, but this goal isn't out of reach for these stocks.

Via The Motley Fool

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

Via Benzinga

3 Inflation-Resilient Stocks to Weather the Economic Turbulence ↗

February 28, 2024

These are the undervalued inflation-resilient stocks to buy as they represent companies that have strong fundamentals.

Via InvestorPlace

EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows ↗

February 28, 2024

Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo...

Via Benzinga

Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors ↗

February 26, 2024

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.

Via Benzinga

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

February 23, 2024

From AstraZeneca

Via Business Wire

Move Over Magnificent 7, Say Hello to the GRANOLAS ↗

February 22, 2024

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

Via InvestorPlace

Why AstraZeneca Stock Is Trading Higher Tuesday ↗

February 20, 2024

FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy....

Via Benzinga

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

February 19, 2024

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

February 19, 2024

From AstraZeneca

Via Business Wire

Cruising For A Bruising ↗

February 18, 2024

We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft...

Via Talk Markets

Topics Economy

Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders ↗

February 17, 2024

LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its...

Via Talk Markets

TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

February 16, 2024

From AstraZeneca

Via Business Wire

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

Via InvestorPlace

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution ↗

February 14, 2024

Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.

Via InvestorPlace

Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report ↗

February 13, 2024

Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.

Via InvestorPlace

Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months. ↗

February 13, 2024

There's more for investors to get excited about in the biopharma world than just weight-loss drugs.

Via The Motley Fool

This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns, Although Still Bullish on Future Growth Potential ↗

February 12, 2024

AstraZeneca reported Q4 2023 sales of $12.02B, up 7%, below consensus. Excluding COVID-19 drugs, revenue increased by 16%. Core EPS was $1.45, missing consensus. BMO Capital maintains Outperform...

Via Benzinga

AstraZeneca Leads The FTSE Lower On Barclay’s Downgrade ↗

February 12, 2024

The pharmaceutical sector saw a decline of 1.6%, with AstraZeneca dropping 2.4% after Barclays lowered its price target for the stock.

Via Talk Markets

From Slack To Surveillance: Here's How Companies Monitor Your Communications With AI ↗

February 10, 2024

In a move reminiscent of George Orwell's surveillance dystopia, companies are now deploying artificial intelligence (AI) to monitor communications on platforms like Slack and Microsoft Teams.

Via Benzinga

Topics Artificial Intelligence

Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys ↗

February 10, 2024

These stocks all trade at less than 17 times their future expected earnings.

Via The Motley Fool

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

All News about AstraZeneca PLC - American Depositary Shares

Starting at $3.75/week.

Subscribe Today